# Bonnie S. Glisson

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/bonnie-s-glisson/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,959 |
| Field | Lung Cancer Research Studies |
| h-index | 82 |
| i10-index | 216 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5110967559 |
| Works | 549 |

## Researcher papers

Showing 12 of 16.

- [Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer](https://scholariq.org/papers/concurrent-chemotherapy-and-radiotherapy-for-organ-preservation-in-advanced/)
- [Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs](https://scholariq.org/papers/using-multiplexed-assays-of-oncogenic-drivers-in-lung-cancers-to-select-targeted/)
- [Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer](https://scholariq.org/papers/long-term-results-of-rtog-91-11-a-comparison-of-three-nonsurgical-treatment/)
- [Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities](https://scholariq.org/papers/patterns-of-transcription-factor-programs-and-immune-pathway-activation-define/)
- [Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer](https://scholariq.org/papers/targeting-dna-damage-response-promotes-antitumor-immunity-through-sting-mediated/)
- [Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225](https://scholariq.org/papers/intensity-modulated-radiation-therapy-with-or-without-chemotherapy-for/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1](https://scholariq.org/papers/proteomic-profiling-identifies-dysregulated-pathways-in-small-cell-lung-cancer/)
- [Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study](https://scholariq.org/papers/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent/)
- [Outcome of Salvage Total Laryngectomy Following Organ Preservation Therapy](https://scholariq.org/papers/outcome-of-salvage-total-laryngectomy-following-organ-preservation-therapy/)
- [Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/adenovirus-mediated-p53-gene-transfer-in-advanced-non-small-cell-lung-cancer/)
- [Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC](https://scholariq.org/papers/landscape-of-egfr-dependent-and-independent-resistance-mechanisms-to-osimertinib/)

## Researcher topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)
- [Salivary Gland Tumors Diagnosis and Treatment](https://scholariq.org/topics/salivary-gland-tumors-diagnosis-and-treatment/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.